Want to see WHWK full AI Analyst Report?
WHWK Stock Chart & Stats
$4.11
--
Market closed
$4.11
--
Day’s Range― - ―
52-Week Range$1.57 - $5.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.35M
Market Cap
$246.33M
Enterprise Value$173.90M
Total Cash (Recent Filing)$145.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 12, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding53,783,330
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue24.34
Enterprise Value/Gross Profit27.26
Enterprise Value/Ebitda-8.47
Forecast
1Y Price Target
$8.00Price Target Upside94.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetA zero-debt balance sheet and a material equity rebound provide lasting financial flexibility for a clinical-stage biotech. This reduces bankruptcy risk, supports multi-year R&D programs, and allows management to fund INDs or strategic deals without immediate refinancing pressure, improving resiliency over months.
PIPE Financing Materially Extends RunwayThe $87.5M PIPE, with meaningful insider and specialist participation, structurally improves near- to medium-term funding visibility. That reduces the cadence and urgency of dilutive raises, enabling consistent development spending and execution on ADC programs over the next 2–12 months while trials progress.
CPT113 Platform Expansion And External ValidationExpanding CPT113 into additional ADC programs and visible clinical activity from partners and peers provides durable pipeline optionality and external validation. Platform breadth and favorable early safety/activity signals can lower platform-specific risk and increase chances of multiple IND-stage assets.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow of this magnitude materially raises financing risk over time. Even with a recent PIPE, continued high burn requires repetition of capital markets access or partnership monetization, which can dilute equity and constrain strategic optionality if clinical progress stalls.
Sharp Revenue Decline And Deeply Negative MarginsA major revenue contraction combined with extreme negative margins shows the business is not generating commercial cashflows and remains R&D-dependent. This structural weakness increases the importance of clinical success and makes sustained operational improvement uncertain absent clear commercial progress.
Negative ROE And Ongoing Value DestructionNegative returns on equity despite fresh capital indicate the company is destroying shareholder value, not yet translating funding into profitable growth. Persistently negative ROE over months undermines long-term investor returns and heightens reliance on new funding or successful asset exits to justify capital deployment.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.57 and its highest was $5.50 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $246.33M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on May 07, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.038.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 53,783,330 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -5.06%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (94.65% Upside)
$8.00 (94.65% Upside)
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.79%
12-Months-Change
Fundamentals
Return on Equity
-79.63%
Trailing 12-Months
Asset Growth
-45.63%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
WHWK Stock 12 Month Forecast
Average Price Target
$8.00
▲(94.65% Upside)
Technical Analysis
Ownership Overview
19.23% Insiders
3.64% Mutual Funds
54.25% Other Institutional Investors
18.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---